Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase‐4 inhibitors: Real world evidence from the Nordic EMPRISE study

AIMS: To evaluate effectiveness and healthcare resource utilization (HCRU) of empagliflozin versus dipeptidyl peptidase‐4 inhibitors (DPP‐4i) in Swedish clinical practice, as part of the EMPRISE EU study (EUPAS27606, NCT03817463). MATERIALS AND METHODS: A non‐interventional, cohort study using retro...

Descripción completa

Detalles Bibliográficos
Autores principales: Nyström, Thomas, Toresson Grip, Emilie, Gunnarsson, Joel, Casajust, Paula, Karlsdotter, Kristina, Skogsberg, Josefin, Ustyugova, Anastasia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092061/
https://www.ncbi.nlm.nih.gov/pubmed/36097728
http://dx.doi.org/10.1111/dom.14870

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092061/
https://www.ncbi.nlm.nih.gov/pubmed/36097728
http://dx.doi.org/10.1111/dom.14870

Ejemplares similares